Noxafil delayed-release tablets had a market value of approximately $325 million for the 12 months ended June 2019, although actual generic market values are expected to be lower.
Lannett expects to commercialize products in the oncolytic and hormonal therapeutic categories, including injectables, that are within Cediprof's development and manufacturing capabilities.
Fulvestrant injection, 250 mg/5 mL (50 mg/mL) had a market value of approximately $549.9 million for the 12 month period ending June 2019, according to IQVIA.